Abstract
Get full access to this article
View all access options for this article.
References
1.
Loehrer
PJ
Einhorn
LH
. Cisplatin . Ann Intern Med
1984 ;100 :704 –13 .
2.
Menard
O
Martinet
Y
Lamy
P
. Cisplatin-induced atrial fibrillation . J Clin Oncol
1991 ;9 :192 –3 .
3.
Petrella
V
Alciato
P
Cantone
PA
Fico
D
Gagliardini
R
. High-frequency atrial arrhythmia induced by a cisplatin—etoposide combination . Minerva Med
1989 ;80 :305 –7 .
4.
Connobio
L
Fassio
T
Gasparini
G
Caruso
G
Barzan
L
Comeretto
R
Cardiac arrhythmia: Possible complication from treatment with cisplatin . Tumori
1986 ;72 :201 –4 .
5.
Hochster
H
Wasserheit
C
Speyer
J
. Cardiotoxicity and cardioprotection during chemotherapy . Curr Opin Oncol
1995 ;7 :304 –9 .
6.
Hashimi
LA
Khaly
MF
Salem
PA
. Supraventricular tachycardia. A probable complication of platinum treatment . Oncology
1984 ;41 :174 –5 .
7.
Schlaeffer
F
Tovi
F
Leiberman
A
. Cisplatin-induced bradycardia . Drug Intell Clin Pharm
1983 ;17 :899 –901 .
8.
Blackley
JO
Hill
JB
. Renal and electrolyte disturbances associated with cisplatin . Ann Intern Med
1981 ;95 :628 –32 .
9.
Sartori
S
Nielsen
I
Tassinari
D
Rigolin
F
Arcudi
D
Abbasciano
V
. Changes in intracellular magnesium concentrations during cisplatin therapy . Oncology
1993 ;53 :230 –4 .
10.
Stamatopulos
K
Kanellopoulou
G
Vaiopoulos
G
Stamatellos
G
Yatanagas
X
. Evidence for sinoatrial blockade associated with high dose cytarabine therapy . Leuk Res
1998 ;22 :759 –61 .
11.
Lucas
KG
Howrie
DL
Phebus
CK
. Cardiorespiratory decompensation following methylprednisolone administration . Pediatr Hematol Oncol
1993 ;10 :249 –55 .
12.
Naranjo
CA
Busto
U
Sellers
EM
Sandor
P
Ruiz
I
Roberts
EA
A method for estimating the probability of adverse drug reactions . Clin Pharmacol Ther
1981 ;30 :239 –45 .